Atlas Trials

Brentuximab Vedotin and Pembrolizumab in Treating Patients With Recurrent Peripheral T-Cell Lymphoma

Clinical trial NCT04795869 · WITHDRAWN

Trial details

NCT number
NCT04795869
Sponsor
Northwestern University
Status
WITHDRAWN
Phase
Phase 2
Study type
INTERVENTIONAL
Recurrent Angioimmunoblastic T-Cell LymphomaRecurrent Enteropathy-Associated T-Cell LymphomaRecurrent Follicular T-Cell LymphomaRecurrent Hepatosplenic T-Cell LymphomaRecurrent Nodal Peripheral T-Cell Lymphoma With TFH PhenotypeRecurrent Peripheral T-Cell Lymphoma, Not Otherwise SpecifiedRecurrent Subcutaneous Panniculitis-Like T-Cell LymphomaRefractory Angioimmunoblastic T-Cell LymphomaRefractory Enteropathy-Associated T-Cell LymphomaRefractory Follicular T-Cell LymphomaRefractory Hepatosplenic T-Cell LymphomaRefractory Nodal Peripheral T-Cell Lymphoma With TFH Phenotype
Start date
2020-03-01
Primary completion
2026-03-15
Enrollment
0

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.